BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 18279734)

  • 1. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drug-eluting stents for diabetic patients. A critical appraisal of the currently available data from randomized trials].
    Silber S; Herdeg C
    Herz; 2008 Apr; 33(3):196-205. PubMed ID: 18568314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents.
    Caixeta A; Leon MB; Lansky AJ; Nikolsky E; Aoki J; Moses JW; Schofer J; Morice MC; Schampaert E; Kirtane AJ; Popma JJ; Parise H; Fahy M; Mehran R
    J Am Coll Cardiol; 2009 Sep; 54(10):894-902. PubMed ID: 19712798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term paclitaxel-eluting stent outcomes in elderly patients.
    Forman DE; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Wei JY; Joshi AA; Dawkins KD; Baim DS
    Circ Cardiovasc Interv; 2009 Jun; 2(3):178-87. PubMed ID: 20031714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry.
    Williams DO; Abbott JD; Kip KE;
    Circulation; 2006 Nov; 114(20):2154-62. PubMed ID: 17060386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry).
    Kaltoft A; Jensen LO; Maeng M; Tilsted HH; Thayssen P; Bøttcher M; Lassen JF; Krusell LR; Rasmussen K; Hansen KN; Pedersen L; Johnsen SP; Sørensen HT; Thuesen L
    J Am Coll Cardiol; 2009 Feb; 53(8):658-64. PubMed ID: 19232897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
    Banning AP; Westaby S; Morice MC; Kappetein AP; Mohr FW; Berti S; Glauber M; Kellett MA; Kramer RS; Leadley K; Dawkins KD; Serruys PW
    J Am Coll Cardiol; 2010 Mar; 55(11):1067-75. PubMed ID: 20079596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry.
    Garg P; Normand SL; Silbaugh TS; Wolf RE; Zelevinsky K; Lovett A; Varma MR; Zhou Z; Mauri L
    Circulation; 2008 Nov; 118(22):2277-85, 7p following 2285. PubMed ID: 19001019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
    Mahmud E; Bromberg-Marin G; Palakodeti V; Ang L; Creanga D; Demaria AN
    J Am Coll Cardiol; 2008 Jun; 51(25):2385-95. PubMed ID: 18565394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
    Hermiller JB; Raizner A; Cannon L; Gurbel PA; Kutcher MA; Wong SC; Russell ME; Ellis SG; Mehran R; Stone GW;
    J Am Coll Cardiol; 2005 Apr; 45(8):1172-9. PubMed ID: 15837245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
    Stone GW; Ellis SG; Colombo A; Dawkins KD; Grube E; Cutlip DE; Friedman M; Baim DS; Koglin J
    Circulation; 2007 Jun; 115(22):2842-7. PubMed ID: 17515458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
    Schömig A; Dibra A; Windecker S; Mehilli J; Suárez de Lezo J; Kaiser C; Park SJ; Goy JJ; Lee JH; Di Lorenzo E; Wu J; Jüni P; Pfisterer ME; Meier B; Kastrati A
    J Am Coll Cardiol; 2007 Oct; 50(14):1373-80. PubMed ID: 17903638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials.
    Kumbhani DJ; Bavry AA; Kamdar AR; Helton TJ; Bhatt DL
    Am Heart J; 2008 Apr; 155(4):640-7. PubMed ID: 18371470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis.
    Bavry AA; Kumbhani DJ; Helton TJ; Bhatt DL
    J Am Coll Cardiol; 2005 Mar; 45(6):941-6. PubMed ID: 15766833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.